Biperiden
When ATH:
N04AA02
Characteristic.
The white crystalline powder, without smell, slightly soluble in water and alcohol.
Pharmacological action.
Antiparkinsonian.
Application.
Syndrome parkinsonizma, Parkinson's disease, extrapyramidal disorder, dyskinesias, akinezii, drug induced, incl. neuroleptics.
Contraindications.
Hypersensitivity, zakrыtougolynaya glaucoma, megacolon, obstruction of the digestive tract, integuments, prostatauxe, pregnancy, breast-feeding.
Pregnancy and breast-feeding.
Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)
Side effects.
From the nervous system and sensory organs: fatigue, weakness, dizziness, drowsiness, alarm, confusion, euphoria, memory impairment, hallucinations, midriaz, ccomodation.
Cardio-vascular system and blood (hematopoiesis, hemostasis): tachycardia / bradycardia, low blood pressure.
From the digestive tract: dry mouth, dyspeptic disorders.
Other: allergic reactions, strangury, drug dependence.
Cooperation.
It enhances the effects of anticholinergics, antihistamines, antiparkinsonian and anticonvulsants, ters-metoclopramide. Incompatible with alcohol. Quinidine increases the impact holinoliticheskoe, levodopa is the risk of psoriasis.
Overdose.
Symptoms: expressed holinoliticheskie effects.
Treatment: symptomatic. Perhaps the use of cholinesterase inhibitors.
Dosing and Administration.
Inside, I / or / m. The dosage and frequency of administration are selected individually, depending on the indication and the patient's age.
Precautions.
Be wary appoint cerebrovascular (advanced age), patients with epilepsy (should consider the possibility of seizures). Stop treatment gradually (high probability of withdrawal). Patients, receiving the drug, It should refrain from activities potentially hazardous activities, requiring speed of mental and motor reactions.
Cooperation
| Active substance | Description of interaction |
| Acrivastine | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Amitriptyline | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Haloperidol | FMR: synergism. Enhances increased intraocular pressure, It increases the risk of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Difengidramin | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Imipramine | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Quetiapine | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Clemastine | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Klozapyn | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Clomipramine | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Lithium carbonate | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Loratadine | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Maprotilin | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Metoclopramide | FMR: antagonizm. Against the backdrop of weaker effect biperiden. |
| Oxybutynin | FMR: synergism. Increases (mutually) frequency and / or severity of anticholinergic side effects (dry mouth, constipation, drowsiness and others). |
| Olanzapine | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Perfenazyn | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Promethazine | FMR: synergism. Strengthens (mutually) holinolitichesky effect; with a joint appointment caution (Perhaps the Central antiholinergicski syndrome — atropinopodobnaja intoxication). |
| Risperidone | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Tioridazin | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Trifluoperazine | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Fexofenadine | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Quinidine | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Chlorpromazine | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Chlorprothixene | FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Cetirizine | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Ciprogeptadin | FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication). |
| Ethanol | It enhances the effect deprimiriruyuschy; the period of treatment is necessary to eliminate the use of alcohol. |
